Schroeder Thilo

About Schroeder Thilo

Dr. Thilo Schroeder is best known publicly for his role as a board director at PMV Pharmaceuticals, Inc., a Nasdaq-listed biotechnology company focused on p53-targeted cancer therapies. PMV’s investor-relations and governance materials, together with a company press release, show that he served on the board and later stepped down in 2022, when Carol Gallagher was appointed to replace him. The company explicitly thanked him for his contributions, underscoring that he played a meaningful governance role during an important phase of PMV’s development. SEC filings also identify him as a director connected to PMV Pharmaceuticals, confirming his long-running involvement in the company’s oversight. ([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-appoints-industry-veteran-dr-carol-0?utm_source=openai)) Based on the sources reviewed, his public profile is more closely associated with board-level oversight and life-sciences investing/advisory work than with a traditional operating executive title such as CEO or CFO. The available materials do not provide a full, detailed operating-career timeline, so it is best to stay conservative. What can be said with confidence is that he helped oversee a company working on innovative oncology science, in particular a p53-centered precision-oncology strategy. In that context, his role would have involved the core responsibilities of an independent director: strategic review, oversight of governance and risk, support for financing and capital-allocation decisions, and long-term value creation. ([ir.pmvpharma.com](https://ir.pmvpharma.com/news-releases/news-release-details/pmv-pharmaceuticals-appoints-industry-veteran-dr-carol-0?utm_source=openai)) His tenure at PMV Pharmaceuticals coincided with a critical stage in the company’s evolution, including continued advancement of its scientific platform and capital-raising activities to fund research and development. While the sources do not attribute specific standalone decisions to him, they do show that he was part of the board during a period when PMV was building its clinical and corporate foundation as a public biotech company. That makes his profile relevant for executive, governance, and board-leadership SEO contexts, even if the publicly available record remains focused on board service rather than a broader biography. ([ir.pmvpharma.com](https://ir.pmvpharma.com/node/6331/pdf?utm_source=openai))